Fundraising Fox
/Companies
Sign in

ProJenX

Nissequogue, US · Founded 2021 · Delaware corporation · 9 employees on LinkedIn · 2 known investors

Find your way into ProJenX

Sign up to see every warm intro you have to ProJenX

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the ProJenX team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.

BiotechDeep TechMedical Devices

Founders & leadership

VE
Valerie EstessNamed on SEC filing
JE
Jenifer Estess
EL
Emily LowryDirector of Internal Operations at the Project ALS Therapeutics Core at Columbia
AZ
Arie ZaskFacility Manager for the Columbia University Chemical Probe Synthesis Facility

Board

JPJohn Prufeta
John PrufetaBoard directorChief Executive Officer and Managing Partner at Medical Excellence Capital
EHEric Heil
Eric HeilChair & Board Member (Served as interim founding CEO)Managing Partner at Medical Excellence Capital
JMJoni Mancini
Joni ManciniBoard directorManaging Partner at Medical Excellence Capital
BR
Brent R. StockwellChair of the Department of Biological Science, Professor at Columbia University
HW
Hynek WichterleJerry and Emily Spiegel Professor at Columbia University

Investors · 2

ALS Investment Fundlisted by ALS Investment FundAmsterdam

How we know: ALS Investment Fund's portfolio page · Not right? Tell us

Funding

SEC filings, press & company announcements

$5.1M disclosed across 1 of 2 rounds · 2021–2023

▶$5.1MraisedJan 2022 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John PrufetaDirector
  • Eric HeilDirector
  • Joni ManciniExecutive Officer
  • Hynek WichterleDirector
  • Valerie EstessDirector
Offering amount
$6M
Amount sold
$5.1M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
SpinogenixSpinogenix is a biopharmaceutical company developing therapies to restore synaptic function, with a pipeline aimed at neurological and neurodegenerative conditions.
PredxbioPredxBio develops tissue analysis software that uses spatial multi-omics data to identify biomarkers and inform drug development decisions. The platform helps pharmaceutical and biotech companies move from exploratory tissue analysis to clinical development with explainable insights about cell states, microenvironments, and therapeutic response patterns.
PrecigenPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
arGEN-XThe company develops therapies for people with severe autoimmune diseases.

Companies working in the same space as ProJenX.

In the news

ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association - ProjenX WordPress Siteprojenx.com · Jun 2024

Frequently asked questions

What does ProJenX do?
ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.
Who are ProJenX's investors?
ProJenX's investors include Medical Excellence Capital, ALS Investment Fund.
How much funding has ProJenX raised?
ProJenX has disclosed $5.1M raised across 1 of its 2 known rounds.
Where is ProJenX headquartered?
ProJenX is headquartered in Nissequogue, US.